The TGF-β pathway increases the expression of tyrosine kinase receptors, such as IGF1R, EGFR, PDGFβR, and FGFR1 in HCC cells, which counterbalances sorafenib’s ability to induce apoptosis [146]. The gene discussed is FGFR1; the disease is hepatocellular carcinoma.